NEWARK, Del., August 9, 2022 /PRNewswire/ — The National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL) is pleased to announce approximately $15.8M in planned project activities through the Institute’s Call 5.2 for 14 new technology and workforce development projects that will help capture key innovation opportunities in the industry biopharmaceutical.
These projects have been selected to best align with the key areas of interest identified by NIIMBL and best match industry needs.
“NIIMBL looks forward to adding these projects to our technology portfolio, advancing our community’s efforts in the key areas of cell processing, measurement of critical quality attributes and process variables during biopharmaceutical manufacturing, as well as to improve reliability and ensure quality during these manufacturing processes,” states chris robertassociate director of the institute.
The 5.2 call for projects also included several workforce development projects that provide a variety of opportunities for those interested in entering or developing skills within the biopharmaceutical manufacturing industry.
“The new slate of workforce projects will advance NIIMBL’s workforce and talent development mission by driving industry adoption of alternative pathways in the industry, increasing the awareness of biopharmaceutical manufacturing careers in diverse populations, as well as catalyzing new training and professional development in cell therapy, gene therapy and mRNA vaccine manufacturing,” adds John BalchunasDirector of Workforce Development.
To date, NIIMBL has awarded approximately 100 technical, workforce development and Global Health Fund projects through the RFP process with a total investment of more than $95 million since 2017, when the Institute was launched. The NIIMBL community is made up of more than 200 members from academia, industry, government, and not-for-profit organizations all sharing a common goal of advancing biopharmaceutical manufacturing.
For a description of each project and to learn more about NIIMBL, please visit the Project Call 5.2 website.
5.2 List of projects
Project: Integrated Continuous USP Platform for Maximum Productivity and Closed-Loop Controlled AQC
Conduct: University of Massachusetts System
Participant(s): Massachusetts Institute of TechnologyWhirlcell LLC., Yokogawa Corporation of America, Pfizer, Inc.
Project: Real-Time Absolute Quantification of Critical Bioprocessing Metabolites with the AI-Powered Pyxis™ Metabolomics Platform
Conduct: Matterworks, Inc.
Participant(s): Sartorius Stedim, Eli Lilly and company
Project: Innovative scalable technologies for the production of cell therapies
Conduct: University of Delaware
Participant(s): MilliporeSigma/EMD Serono, Agilent
Project: An integrated platform for fully automated, continuous and real-time multi-attribute monitoring of upstream processes for the production of glycosylated monoclonal antibodies
Conduct: Rutgersthe state university of New Jersey
Participant(s): University of DelawareAgilent, Endress + Hauser Optical Analysis,
Project: Virus and Endotoxin Removal Strategies for Safe and Reliable AAV Production
Participant(s): Pall Corporation/Cytiva
Project: Advanced bioprocessing sensor and analytical technologies for online monitoring and automation of induced pluripotent stem cell culture
Conduct: Northeastern University
Participant(s): Agile, Clemson UniversityMilliporeSigma/EMD Serono, Physical Sciences Inc., University of Massachusetts System
Project: Rapid machine-guided decision making on the quality of viruses as products and for the determination of viral clearance
Conduct: Carnegie Mellon University
Participant(s): Sartorius Stedim
Project: Modernization of Host Cell Protein Clearance and Quantitation in mAb Manufacturing
Conduct: University of Delaware
Participant(s): Bristol-Myers SquibbNational Institute of Standards and Technology, Genentech, LigaTrap Technologies, LLC, Merck & Co., Inc., North Carolina State UniversityPfizer, Inc., Rensselaer Polytechnic Institute
Project: Timed Raman spectroscopy to improve chemical sensitivity for in situ monitoring of bioreactors
Conduct: National Institute of Pharmaceutical Technology and Education, Inc. (NIPTE) (Duquesne University)
Participant(s): Pfizer, Inc.
Project: Biofabrication Technician Apprenticeship Program
Conduct: MassBio Education Foundation
Participant(s): Northeastern University
Project: Promoting careers in biopharmaceutical manufacturing operations to high school students
Conduct: North Carolina Biotechnology Center
Participant(s): Merck & Co., Inc., Pfizer, Inc., Pitt Community College
Project: A public-private partnership strategy for training the workforce in the manufacture of cell and gene therapies
Conduct: University of California, Davis
Participant(s): Eli Lilly and Company, Pall Corporation/Cytiva, Solano College
Project: Gateway to Bio
Conduct: University of Virginia
Participant(s): Merck & Co., Inc., Pfizer, Inc.
Project: Modular Training for Vaccine Development and Manufacturing Workforce
Conduct: Massachusetts Institute of Technology
Participant(s): Merck & Co., Inc., Quincy CollegeSanofi
*All funding is subject to project agreement negotiations.
The National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient manufacturing capabilities and fast, and to educate and train a world-class biopharmaceutical manufacturing workforce. , fundamentally advancing the competitiveness of the United States in this industry. NIIMBL is part of Manufacturing USA®, a diverse network of federally sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the U.S. Department’s National Institute of Standards and Technology (NIST). trade with significant additional support from its members.
Maria X. Chacon
Marketing and Communications Director
SOURCE National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL)